查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
尿路感染治療市場：按藥物、適應症、地區劃分——規模、份額、展望、機會分析，2022-2028 年
市場調查報告書
商品編碼
1149888

尿路感染治療市場：按藥物、適應症、地區劃分——規模、份額、展望、機會分析，2022-2028 年

Urinary Tract Infection Therapeutic Market, By Drug, By Indication, and By Geography - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028
出版日期: | 出版商: Coherent Market Insights | 英文 197 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

尿路感染 (UTI) 是一種影響泌尿系統任何部分的感染。與男性相比，女性患尿路感染的風險更高。尿路感染 (UTI) 通常是由糞便中的細菌進入尿路引起的。通常首先使用抗生素治療尿路感染。單純性尿路感染常用藥物有甲氧芐氨嘧啶磺胺甲噁唑（Bactrim、Bactrim DS）、磷黴素（Monurol）、夫喃妥因（Macrodantin、Macrobid、Furadantin）、頭孢氨芐、ceftoria Kison等。

市場動態。

尿路感染的高患病率、糖尿病和腎結石患病率的上升、老年人口的增加、對開發新療法的日益關注等將在預測期內推動全球尿路感染治療市場。是其中之一預計推動增長的主要因素

2021 年 10 月，Spero Therapeutics, Inc. 尋求美國食品和藥物管理局 (FDA) 批准替比培南 HBr 片劑用於治療複雜性尿路感染 (cUTI)，包括易感微生物引起的腎盂腎炎。藥物申請 (NDA) 已提交給美國食品和藥物管理局。此外，2021年9月，BDR Pharma推出了用於腹腔內感染、下呼吸道感染和復雜尿路感染患者的比阿培南。

2019年7月，美國食品藥品監督管理局（FDA）批准抗菌藥物利卡比南（亞胺培南、西司他丁、瑞巴坦）已獲批。

這項研究的主要特點

  • 本報告對全球尿路感染治療市場進行了深入分析，提供了以 2021 年為基準年的預測期（2022-2028 年）的市場規模和復合年增長率 (CAGR%)。
  • 它還闡明了各個細分市場的潛在創收機會，並描述了針對該市場的一系列有吸引力的投資建議。
  • 它還提供有關市場驅動因素、制約因素、機會、新產品發布或批准、市場趨勢、區域前景以及主要參與者採用的競爭策略的重要見解。
  • 它根據以下參數（包括公司亮點、產品組合、主要亮點、績效和戰略）介紹了全球尿路感染治療市場的主要參與者。
  • 參與這項研究的主要公司包括輝瑞、諾華、西普拉、拜耳、阿斯利康、鹽野義和葛蘭素史克。
  • 這份報告中的見解將使營銷人員和企業高管能夠就未來的產品發布、類型升級、市場擴張和營銷策略做出明智的決策。我猜。
  • 《全球尿路治療市場》報告面向該行業的各種利益相關者，包括投資者、供應商、產品製造商、分銷商、新進入者和金融分析師。
  • 利益相關者將能夠通過用於分析全球尿路感染治療市場的各種戰略矩陣來促進決策制定。

內容

第 1 章目的和先決條件

  • 調查目的
  • 先決條件
  • 縮寫說明

第二章市場展望

  • 報告內容
    • 市場定義和範圍
  • 執行摘要
    • 尿路感染治療市場：按藥物分類
    • 尿路感染治療市場：按適應症分類
    • 尿路感染治療市場：按地區
  • 連貫機會圖 (COM)

第3章市場動態、規律及趨勢分析

  • 市場動態
    • 全世界尿路感染的高發率
    • 與使用尿路感染治療相關的副作用
    • 越來越關注新藥開發
  • 影響分析
  • 主要亮點
  • 監管情景
  • 產品發布/批准
  • 害蟲分析
  • 對 PORTER 的分析
  • 合併/收購場景

第 4 章全球尿路感染治療市場：冠狀病毒 (COVID-19) 大流行的影響

  • COVID-19 的流行病學特徵
  • 供應方和需求方分析
  • 經濟影響

第 5 章全球尿路感染治療市場：按藥物分類，2017-2028

  • 青黴素和伴隨藥物
  • 奎諾酮類
  • 頭孢類
  • 唑和兩性黴素 B
  • 硝基夫喃
  • 其他藥物

第 6 章全球尿路感染治療市場：按適應症分類，2017-2028

  • 複雜性尿路感染
  • 非全身性尿路感染
  • 其他適應症

第 7 章全球尿路感染治療市場：按地區劃分，2017-2028

  • 北美
  • 歐洲
  • 亞太地區
  • 拉丁美洲
  • 中東和非洲
  • 世界其他地方

第八章競爭格局

  • Pfizer
  • Novartis AG
  • Cipla Inc.
  • Bayer AG
  • AstraZeneca
  • Shionogi & Co. Ltd.
  • GlaxoSmithKline PLC

第 9 章

  • 調查方法
  • 關於出版商
簡介目錄
Product Code: CMI1178

A urinary tract infection (UTI) is an infection in any part of the urinary system. Women are at greater risk of developing a urinary tract infection compared to men. Urinary tract infections (UTIs) are usually caused by bacteria from poo entering the urinary tract. Antibiotics usually are the first treatment for urinary tract infections. Medicines commonly used for simple UTI s include Trimethoprim and sulfamethoxazole (Bactrim, Bactrim DS), Fosfomycin (Monurol), Nitrofurantoin (Macrodantin, Macrobid, and Furadantin), Cephalexin, and Ceftriaxone.

Market Dynamics:

High prevalence of urinary tract infection, increasing prevalence of diabetes and kidney stones, increasing geriatric population, and increase in focus on the development of novel therapeutics are some major factors expected to drive growth of the global urinary tract infection therapeutic market during the forecast period.

In October 2021, Spero Therapeutics Inc. submitted a new drug application (NDA) to the U.S. Food and Drug Administration (USFDA), seeking approval for tebipenem HBr tablets for the treatment of complicated urinary tract infections (cUTI), including pyelonephritis, caused by susceptible microorganisms. Moreover, in September 2021, BDR Pharma launched biapenem for the treatment of patients with intra-abdominal infections, lower respiratory infections, or complicated urinary tract infections.

In July 2019, the U.S. Food and Drug Administration (FDA) approved Recarbrio (imipenem, cilastatin and relebactam), an antibacterial drug product to treat adults with complicated urinary tract infections (cUTI) and complicated intra-abdominal infections (cIAI).

Key features of the study:

  • This report provides in-depth analysis of the global urinary tract infection therapeutic market, and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period (2022-2028), considering 2021 as the base year.
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
  • It profiles key players in the global urinary tract infection therapeutic market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies.
  • Key companies covered as a part of this study include Pfizer, Novartis AG, Cipla Inc., Bayer AG, AstraZeneca, Shionogi & Co. Ltd., and GlaxoSmithKline PLC.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
  • The global urinary tract infection therapeutic market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global urinary tract infection therapeutic market.

Detailed Segmentation:

  • Global Urinary Tract Infection Therapeutic Market By Drug:
    • Penicillin and Combinations
    • Quinolones
    • Cephalosporin
    • Azoles and Amphotericin B
    • Nitrofurans
    • Other Drugs
  • Global Urinary Tract Infection Therapeutic Market By Indication;
    • Complicated UTI
    • Uncomplicated UTI
    • Other Indications
  • Global Urinary Tract Infection Therapeutic Market By Geography:
    • North America
    • Europe
    • Asia-Pacific
    • Middle East and Africa
    • South America
  • Company Profiles:
    • Pfizer
    • Novartis AG
    • Cipla Inc.
    • Bayer AG
    • AstraZeneca
    • Shionogi & Co. Ltd.
    • GlaxoSmithKline PLC

Table of Contents:

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Urinary Tract Infection Therapeutic, By Drug
    • Market Urinary Tract Infection Therapeutic, By Indication
    • Market Urinary Tract Infection Therapeutic, By Geography
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • High prevalence of urinary tract infection across the globe
    • Adverse effects associated with the use of UTI medication
    • Increase in focus on the development of novel drugs
  • Impact Analysis
  • Key Highlights
  • Regulatory Scenario
  • Product launch/Approvals
  • PEST Analysis
  • PORTER's Analysis
  • Merger and Acquisition Scenario

4. Global Urinary Tract Infection Therapeutic Market - Impact of Coronavirus (COVID-19) Pandemic

  • COVID-19 Epidemiology
  • Supply Side and Demand Side Analysis
  • Economic Impact

5. Global Urinary Tract Infection Therapeutic Market, By Drug, 2017-2028, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2022 and 2028 (%)
    • Y-o-Y Growth Analysis, 2017 - 2028
    • Segment Trends
  • Penicillin and Combinations
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2028,(US$ Mn)
  • Quinolones
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2028,(US$ Mn)
  • Cephalosporin
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2028,(US$ Mn)
  • Azoles and Amphotericin B
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2028,(US$ Mn)
  • Nitrofurans
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2028,(US$ Mn)
  • Other Drugs
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2028,(US$ Mn)

6. Global Urinary Tract Infection Therapeutic Market, By Indication, 2017-2028, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2022 and 2028 (%)
    • Y-o-Y Growth Analysis, 2017 - 2028
    • Segment Trends
  • Complicated UTI
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2028,(US$ Mn)
  • Uncomplicated UTI
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2028,(US$ Mn)
  • Other Indications
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2028,(US$ Mn)

7. Global Urinary Tract Infection Therapeutic Market, By Geography, 2017-2028, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2022 and 2028 (%)
    • Y-o-Y Growth Analysis, 2017 - 2028
    • Segment Trends
  • North America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017-2028,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2017-2028,(US$ Mn)
  • Europe
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017-2028,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2017-2028,(US$ Mn)
  • Asia Pacific
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017-2028,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2017-2028,(US$ Mn)
  • Latin America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017-2028,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2017-2028,(US$ Mn)
  • Middle East and Africa
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017-2028,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2017-2028,(US$ Mn)
  • Rest of World
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017-2028,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2017-2028,(US$ Mn)

8. Competitive Landscape

  • Pfizer
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Novartis AG
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Cipla Inc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Bayer AG
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • AstraZeneca
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Shionogi & Co. Ltd.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • GlaxoSmithKline PLC
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Analyst Views

9. Section

  • Research Methodology
  • About us